# Astrana Health, Inc.: Form 10-K/A for the period ended Dec 31, 2022

- Company: [Astrana Health, Inc.](/companies/asth.md) (CIK 1083446)
- Form: 10-K/A
- Filed: 2023-08-09
- Accepted by EDGAR: Aug 9, 2023, 17:24 ET
- Period: 2022-12-31
- Accession: 0001628280-23-028675
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1083446/000162828023028675/ameh-20221231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1083446/000162828023028675/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-10-01 to 2022-12-31 | $294.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months, 2022-01-01 to 2022-12-31 | $1.14bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Operating income | 3 months, 2022-10-01 to 2022-12-31 | $12.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months, 2022-01-01 to 2022-12-31 | $104.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2022-01-01 to 2022-12-31 | $7.9m | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-10-01 to 2022-12-31 | $11.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months, 2022-01-01 to 2022-12-31 | $40.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-10-01 to 2022-12-31 | −$3.7m | us-gaap:NetIncomeLoss |
| Net income | 12 months, 2022-01-01 to 2022-12-31 | $45.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-10-01 to 2022-12-31 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months, 2022-01-01 to 2022-12-31 | $0.99 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-10-01 to 2022-12-31 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months, 2022-01-01 to 2022-12-31 | $1.00 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2022-01-01 to 2022-12-31 | 45,602,415 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2022-01-01 to 2022-12-31 | $82.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2022-01-01 to 2022-12-31 | $22.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months, 2022-01-01 to 2022-12-31 | $14.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 12 months, 2022-01-01 to 2022-12-31 | $9.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2022-12-31 | $288.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-12-31 | $428.1m | us-gaap:AssetsCurrent |
| Total assets | at 2022-12-31 | $966.2m | us-gaap:Assets |
| Current liabilities | at 2022-12-31 | $148.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-12-31 | $407.7m | us-gaap:Liabilities |
| Long-term debt | at 2022-12-31 | $203.4m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2022-12-31 | $619.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2022-12-31 | $542.6m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1083446/000162828023028675/ameh-20221231.htm

Filed Aug 9, 2023.
Source: SEC EDGAR, the filing index for accession 0001628280-23-028675. Last ingested by Listed: Nov 14, 2026, 19:58 ET. No prices; not investment advice.
